Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Non-Regulatory

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Non-Regulatory

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Non-Regulatory

Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market

Regulatory

Allarity Therapeutics Announces Delisting and Last Day of Trading in the Company’s Shares on Nasdaq First North

Regulatory

Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North

Regulatory

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

Regulatory

Grant of New Warrants and Resolutions on Existing Warrants

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – September 2021

Regulatory

Minutes of Extraordinary General Meeting held on 22 November 2021

Regulatory

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Regulatory

NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021

Regulatory

U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq

Regulatory

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Regulatory

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Regulatory

Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3

Regulatory

Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3

Regulatory

MINUTES OF EXTRAORDINARY GENERAL MEETING 2021

Regulatory

Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021

Regulatory

Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – June 2021

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.